ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

CordenPharma to make lipids for Moderna’s COVID-19 vaccine candidate

by Rick Mullin
May 29, 2020 | APPEARED IN VOLUME 98, ISSUE 21

 

CordenPharma and Moderna have extended a contract for CordenPharma to manufacture large volumes of the lipid excipients that the biotech firm uses to make its COVID-19 vaccine candidate, mRNA-1273. The agreement extends a 2016 pact for lipid production at the Swiss facility of the German contract drug production firm. The extension will expand work for Moderna to include CordenPharma’s plants in France and the US. The US government has committed $483 million to Moderna for development and scale-up of the vaccine.

C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment